Read by QxMD icon Read

SF-36 and encephalopathy

Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz, Christian Gluud
BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). However, it is still questionable if eradication of hepatitis C virus in the blood eliminates hepatitis C in the body, and improves survival and leads to fewer complications...
June 6, 2017: Cochrane Database of Systematic Reviews
Henning Pflugrad, Anita B Tryc, Annemarie Goldbecker, Christian P Strassburg, Hannelore Barg-Hock, Jürgen Klempnauer, Karin Weissenborn
AIM: To investigate the impact of hepatic encephalopathy before orthotopic liver transplantation (OLT) and neurological complications after OLT on employment after OLT. METHODS: One hundred and fourteen patients with chronic liver disease aged 18-60 years underwent neurological examination to identify neurological complications, neuropsychological tests comprising the PSE-Syndrome-Test yielding the psychometric hepatic encephalopathy score, the critical flicker frequency and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), completed a questionnaire concerning their occupation and filled in the short form 36 (SF-36) to assess health-related quality of life before OLT and 12 mo after OLT, if possible...
April 8, 2017: World Journal of Hepatology
Zobair M Younossi, Maria Stepanova, Michael Charlton, Michael P Curry, Jacqueline G O'Leary, Robert S Brown, Sharon Hunt
BACKGROUND: Hepatitis C virus (HCV) treatment regimens with direct-acting antivirals have not been extensively studied in patients with decompensated cirrhosis. We assessed patient-reported outcomes (PROs) in patients with decompensated cirrhosis given a fixed-dose combination of sofosbuvir and velpatasvir with and without ribavirin. METHODS: This study was an exploratory analysis of data collected in a randomised, open-label phase 3 trial (ASTRAL-4) in which patients with HCV-related decompensated cirrhosis were randomly assigned to an all-oral fixed-dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks, sofosbuvir and velpatasvir plus oral ribavirin (weight-based 1000 mg or 1200 mg) for 12 weeks, or sofosbuvir and velpatasvir for 24 weeks...
October 2016: Lancet. Gastroenterology & Hepatology
Jatinderpal Singh, Barjesh Chander Sharma, Vinod Puri, Sanjeev Sachdeva, Siddharth Srivastava
Sleep disturbances are common in patients of cirrhosis with minimal hepatic encephalopathy (MHE) and affect health related quality of life (HRQOL). No study has evaluated effect of lactulose on sleep disturbances and correlation with HRQOL in patients with MHE. We assessed sleep disturbances in cirrhosis with MHE and effect of lactulose on sleep disturbances and HRQOL. One hundred patients of cirrhosis [MHE; (n = 50, age 45.3 ± 11.2 years, 45 males) no-MHE (n = 50, age 46.3 ± 10.4 years, 44 males)] were included...
April 2017: Metabolic Brain Disease
Emi Yoshimura, Tatsuki Ichikawa, Hisamitsu Miyaaki, Naota Taura, Satoshi Miuma, Hidataka Shibata, Takuya Honda, Fuminao Takeshima, Kazuhiko Nakao
The diagnosis of minimal hepatic encephalopathy (MHE) is more difficult in comparison to the diagnosis of overt hepatic encephalopathy (OHE), as patients with MHE do not exhibit overt neurological deficits and must be diagnosed using specialized equipment. However, identifying MHE is critical for patients with cirrhosis, and a simple screening test is required. The present study aimed to evaluate the associations between MHE, clinical characteristics and questionnaire items regarding sleep disturbances and cirrhosis-related symptom score (CSS)...
August 2016: Biomedical Reports
L A Belova, O Iu Kolotik-Kameneva, V V Mashin, L V Saprygina, E V Mashin
AIM: To evaluate the efficacy of cytoflavin in the treatment of patients with hypertensive encephalopathy (HE). SUBJECTS AND METHODS: One hundred and forty patients aged 39 to 73 years, diagnosed with HE, were examined and randomized to 2 groups. A study group (n = 74) received cytoflavin in a dose of 2 tablets b.i.d. on days 1 to 25 days inclusive during standard basic therapy. A comparison group (n = 66 persons) had standard basic therapy only. A control group consisted of 30 apparently healthy individuals...
2014: Terapevticheskiĭ Arkhiv
M Akahoshi, T Ichikawa, N Taura, H Miyaaki, T Yamaguchi, E Yoshimura, I Takahara, A Soyama, M Takatsuki, H Kondo, S Eguchi, K Nakao
BACKGROUND: Following improvements in patient and graft survival after liver transplantation (LT), the recipients' quality of life has become an important focus of patient care. Sleep is closely related to physical and mental health; however, sleep disturbances in LT patients have not yet been evaluated. METHODS: We assessed 59 LT patients (aged ≥18 years) between September 2011 and September 2012. The patients completed the restless legs syndrome (RLS), 36-item short-form health survey (SF-36), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS) questionnaires...
December 2014: Transplantation Proceedings
E A Chikhacheva, P V Seliverstov, S I Sitkin, V P Dobritsa, V G Radchenko
AIM: To evaluate the efficacy of the symbiotic Linex used in the combination therapy of liver cirrhosis (LC). SUBJECTS AND METHODS: Seventy-four patients with LC, including 44 who received additionally the symbiotic Linex and 30 who had conventional therapy, were examined. All the patients underwent clinical and biochemical blood tests, abdominal ultrasonography, fecal test for bacteria, gas chromatography-mass spectrometry of the blood composition of microbial markers, number connecting test, and quality-of-life assessment (SF-36)...
2014: Terapevticheskiĭ Arkhiv
Ewa Wunsch, Dorota Koziarska, Małgorzata Milkiewicz, Grzegorz Naprawa, Przemysław Nowacki, Marek Hartleb, Piotr Milkiewicz
BACKGROUND: Liver cirrhosis is associated with latent systemic inflammatory response syndrome as evidenced by elevated levels of proinflammatory cytokines. It has been proposed that inflammatory mediators play a role in the pathogenesis of minimal and overt hepatic encephalopathy (HE); hence, they may also have an effect on health-related quality of life (HRQL). The aim of this study was to investigate the relationship between serum levels of interleukin-1β (IL-1β), IL-6, and IL-18 and the occurrence of minimal HE and HRQL...
December 2013: European Journal of Gastroenterology & Hepatology
Jayanta Samanta, Radha K Dhiman, Amit Khatri, Kiran K Thumburu, Sandeep Grover, Ajay Duseja, Yogesh Chawla
Sleep disturbances are common in patients of cirrhosis and has a significant effect on their health related quality of life (HRQOL). Thus far, no study has demonstrated a systematically studied significant correlation between the sleep disturbance observed and the neuropsychiatric impairment status of patients of cirrhosis. On the basis of PHES, we divided 100 cirrhotics into those having minimal hepatic encephalopathy (MHE) (PHES≤-5) and those not (NMHE). Now, in these MHE (n=46) and NMHE (n=54) patients, sleep disturbance was measured with Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) and HRQOL with SF-36(v2) questionnaire...
June 2013: Metabolic Brain Disease
Silvia Nardelli, Ilaria Pentassuglio, Chiara Pasquale, Lorenzo Ridola, Federica Moscucci, Manuela Merli, Concetta Mina, Massimo Marianetti, Mariangela Fratino, Chiara Izzo, Carlo Merkel, Oliviero Riggio
HRQoL is impaired in cirrhosis. Establishing the relevance of depression, anxiety, alexithymia and cirrhosis stage on the patients' HRQoL. Sixty cirrhotics underwent a neuropsychological assessment, including ZUNG-SDS, STAI Y1-Y2 and TAS-20. Minimal hepatic encephalopathy (MHE) was detected by PHES, HRQoL by Short-Form-36 (SF-36). Depression was detected in 34 patients (57 %, 95%CI = 44-70 %), state-anxiety in 16 (27 %, 95%CI = 15-38 %), trait-anxiety in 17 (28 %, 95%CI = 17-40 %), alexithymia in 14 (31 % 95%CI = 16-46 %) and MHE in 22 (37 %, 95%CI = 24-49 %)...
June 2013: Metabolic Brain Disease
Eva Román, Juan Córdoba, Maria Torrens, Carlos Guarner, German Soriano
INTRODUCTION: Falls are frequent in patients with cirrhosis and cognitive dysfunction and can deteriorate health-related quality of life (HRQoL). OBJECTIVE: To evaluate the relationship between previous falls and HRQoL in patients with cirrhosis. METHODS: We measured HRQoL in 118 outpatients with cirrhosis using the Medical Outcomes Study Short Form (SF-36) questionnaire, grouping items into the Physical Component Score (PCS) and the Mental Component Score (MCS)...
January 2013: European Journal of Gastroenterology & Hepatology
Elsa Solà, Hugh Watson, Isabel Graupera, Fanny Turón, Rogelio Barreto, Ezequiel Rodríguez, Marco Pavesi, Vicente Arroyo, Mónica Guevara, Pere Ginès
BACKGROUND & AIMS: Hyponatremia is common in patients with cirrhosis and ascites and is associated with significant neurological disturbances. However, its potential effect on health-related quality of life (HRQL) in cirrhosis has not been investigated. We aimed at assessing the relationship between serum sodium concentration and other clinical and analytical parameters on HRQL in cirrhosis with ascites. METHODS: A total of 523 patients with cirrhosis and ascites were prospectively investigated...
December 2012: Journal of Hepatology
I B Khlynov, T V Likovskaia, M V Chikunova
UNLABELLED: The aim of this work is to improve the efficiency of treatment and life quality of patients with HCV hepatic cirrhosis (HC) Class C by means of correction of protein-energy insufficiency (PEI) using enteral nutritive mixtures with branched-chain amino acids (BCAA). OBJECT AND METHODS OF RESEARCH: A randomized prospective controlled open research of the efficiency of therapy with enteral nutritive mixtures with BCAA for patients with HCV hepatic cirrhosis Class C (score: 10-12) was conducted...
2012: Experimental & Clinical Gastroenterology
Federica Moscucci, Silvia Nardelli, Ilaria Pentassuglio, Chiara Pasquale, Lorenzo Ridola, Manuela Merli, Oliviero Riggio
BACKGROUND: It has been observed that overt hepatic encephalopathy (HE) is accompanied by a persistent cognitive defect, suggesting that HE may not be fully reversible. The health-related quality-of-life (HRQoL) has been shown to be impaired by cirrhosis, and, according to some reports, influenced by minimal HE. Little is known about the effect of previous HE on HRQoL. AIM: To investigate the relative impact of previous HE and minimal HE on HRQoL in a group of consecutively hospitalized cirrhotic patients...
November 2011: Liver International: Official Journal of the International Association for the Study of the Liver
E R Barantsevich, O V Posokhina
Sixty-eight patients, aged from 40 to 70 years, with discirculatory encephalopathy, I and II stages, have been examined. Thirty-five patients of the main group received non-benzodiazepine tranquilizer adaptol in dose 500 mg 2 times daily in addition to regular vasoactive treatment and 33 patients of the control group received only regular treatment. The following characteristics were assessed at baseline and after 1 month of treatment: complaints and neurological status, anxiety level (the Spielberger-Khanin scale), quality of life (SF-36) and parameters of P300 cognitive evoked potentials...
2011: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Ewa Wunsch, Barbara Szymanik, Michał Post, Wojciech Marlicz, Marta Mydłowska, Piotr Milkiewicz
BACKGROUND: Minimal hepatic encephalopathy (HE) is a serious complication of cirrhosis; however, the impact of minimal HE on health-related quality of life (HRQoL) remains controversial. The Psychometric Hepatic Encephalopathy Score (PHES) remains a 'gold standard' for the assessment of minimal HE, but its results clearly differ between studied populations. AIM: We studied the effect of minimal HE on patient HRQoL. METHODS: Eighty-seven consecutive cirrhotic patients were included...
August 2011: Liver International: Official Journal of the International Association for the Study of the Liver
E R Barantsevich, O V Posokhina, A Iu Smirnova, K G Kurashevich
40 patients with alcoholic encephalopathy, aged from 30 to 60 years, were enrolled in the study. Patients were divided into two groups: 20 patients in the treatment group received vasoactive, antioxidant treatment and neyromidin in dose 15 mg in solution during 10 days and then in tabs in dose 20 mg three times a day during 2 months. The comparison group included 20 patients receiving only vasoactive and antioxidant treatment. To the end of treatment, the positive changes in the state of patients reflected in the decrease in the number of complaints and neurological symptoms were seen in the treatment group...
2011: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Luis Compañy, Pedro Zapater, Miguel Pérez-Mateo, Rodrigo Jover
BACKGROUND/AIMS: The long-term evolution of cirrhotic patients with extrapyramidal signs has not yet been studied. We have investigated the influence of extrapyramidal signs on the prognosis, evolution, and quality of life of patients with liver cirrhosis. METHODS: Forty-six patients with cirrhosis were followed up and 18 of them were reevaluated, a mean of 45 months later. Cognitive impairment was measured with psychometric tests (Trail-Making Test part A, Grooved-Pegboard, Block-Design, Oral Symbol Digit and Stroop Test)...
May 2010: European Journal of Gastroenterology & Hepatology
Iñigo Les, Eduardo Doval, Montserrat Flavià, Carlos Jacas, Guillermo Cárdenas, Rafael Esteban, Jaime Guardia, Juan Córdoba
OBJECTIVE: Improvement of prognosis and availability of diverse therapeutic options for complications of advanced liver disease highlight the importance of health-related quality of life (HRQOL) in cirrhosis. The aim of this study was to identify factors that influence HRQOL and may be potentially treatable in patients with cirrhosis. METHODS: HRQOL was measured in 212 outpatients with cirrhosis using a generic questionnaire (Medical Outcomes Study Form, SF-36) and a liver-specific questionnaire (Chronic Liver Disease Questionnaire, CLDQ)...
February 2010: European Journal of Gastroenterology & Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"